Skip to main content

Table 2 Nine-year absolute risk estimates (and 95%CIs) for cardiovascular and cancer mortality from Kaplan-Meier and cumulative incidence competing risk estimators

From: Standard and competing risk analysis of the effect of albuminuria on cardiovascular and cancer mortality in patients with type 2 diabetes mellitus

Albuminuria status

Cardiovascular mortality risk (%)

Cancer mortality risk (%)

Kaplan-Meier

CICR

Kaplan-Meier

CICR

Normoalbuminuria

11.1 (10.8–11.5)

10.2 (9.9–10.5)

8.0 (7.7–8.3)

7.2 (6.9–7.5)

Albuminuria

21.8 (20.9–22.7)

18.5 (17.8–19.3)

10.7 (10.0–11.5)

8.6 (8.1–9.2)